Barclays’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $941K | Buy |
261,774
+90,462
| +53% | +$325K | ﹤0.01% | 2698 |
|
|
2025
Q1 | $512K | Sell |
171,312
-28,801
| -14% | -$86.1K | ﹤0.01% | 2835 |
|
|
2024
Q4 | $671K | Buy |
200,113
+23,036
| +13% | +$77.2K | ﹤0.01% | 2884 |
|
|
2024
Q3 | $593K | Buy |
177,077
+75,624
| +75% | +$253K | ﹤0.01% | 2897 |
|
|
2024
Q2 | $336K | Sell |
101,453
-44,079
| -30% | -$146K | ﹤0.01% | 2753 |
|
|
2024
Q1 | $588K | Sell |
145,532
-51,555
| -26% | -$208K | ﹤0.01% | 2741 |
|
|
2023
Q4 | $601K | Buy |
197,087
+171,468
| +669% | +$523K | ﹤0.01% | 2904 |
|
|
2023
Q3 | $77K | Buy |
25,619
+10,348
| +68% | +$31.1K | ﹤0.01% | 3414 |
|
|
2023
Q2 | $57K | Sell |
15,271
-23,488
| -61% | -$87.7K | ﹤0.01% | 3613 |
|
|
2023
Q1 | $130K | Buy |
38,759
+12,677
| +49% | +$42.5K | ﹤0.01% | 3392 |
|
|
2022
Q4 | $126K | Sell |
26,082
-10,941
| -30% | -$52.9K | ﹤0.01% | 3338 |
|
|
2022
Q3 | $211K | Sell |
37,023
-9,917
| -21% | -$56.5K | ﹤0.01% | 3048 |
|
|
2022
Q2 | $333K | Sell |
46,940
-15,070
| -24% | -$107K | ﹤0.01% | 2832 |
|
|
2022
Q1 | $448K | Buy |
+62,010
| New | +$448K | ﹤0.01% | 2873 |
|